Breaking News

Ginkgo Bioworks Starts 2-Year WHEAT Manufacturing Program

Ginkgo Bioworks gains a $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems.

By: Rachel Klemovitch

Assistant Editor

Ginkgo Bioworks announced a new contract with the Advanced Research Projects Agency for Health (ARPA-H), alongside partners Tritica Biosciences, US Pharmacopeia (USP), On Demand Pharmaceuticals, and Isolere Bio by Donaldson.  The two-year program, Wheat-based High-efficiency Enzyme and API Technology (WHEAT), aims to establish a new manufacturing process for the distributed production of biologic and small molecule active pharmaceutical ingredients (APIs) using wheat germ cell-free expression...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters